ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Lilly Releases Donanemab Data That Demonstrated Relationship Between Reduction of Amyloid Plaque and Slowing of Cognitive Decline drugs
August 02, 2021Today at the Alzheimer's Association International Conference? (AAIC? 2021), Eli Lilly and Company (NYSE: LLY) presented two new exploratory analyses of data from the Phase 2 TRAILBLAZER-ALZ study. -
Lilly's Donanemab receives U.S. FDA's Breakthrough Therapy Designation for Treatment of Alzheimer's disease drugs
June 29, 2021The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's (NYSE: LLY) investigational antibody therapy for Alzheimer's disease (AD). -
Eli Lilly announces mid-stage trial success for donanemab in Alzheimer’s pharmatimes
January 14, 2021Donanemab, an investigational antibody developed by Eli Lilly, has demonstrated positive results in a phase IIa trial in patients with early-stage Alzheimer’s disease (AD).
Pharma Sources Insight January 2025
